Children 6 and younger with eosinophilic esophagitis (EoE) who were treated with dupilumab developed asthma less often than those treated with oral budesonide, according to a retrospective analysis presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting.
EoE is an allergic disease of the esophagus. In children, the inflammation can make eating difficult, and some refuse food, vomit or don't grow as expected. EoE and asthma are both considered part of the atopic march (also called the allergic march), the sequence in which allergic conditions often appear one after another during childhood, and both involve type 2 inflammation mediated by interleukin 4 and interleukin 13.
“Children with EoE are at higher risk for other allergic diseases, including asthma,” said in a news release study author Kayla Steinberger, MD, PhD, a resident physician in pediatrics at West Virginia University. She noted that whether treating EoE early with a biologic affects later asthma development has not been established.
Methodology
Steinberger analyzed records from the TriNetX Research Network, a multicenter database, covering January 2016 to January 2026. She identified the records of children 6 and younger with EoE who received either dupilumab, an injected biologic that blocks signals driving allergic inflammation, or oral budesonide, a steroid that coats the esophagus.
Children who received dupilumab were excluded from the budesonide group. Children with asthma before the index event, defined as the first qualifying medication plus an EoE diagnosis, were also excluded.
The two groups were propensity score matched for baseline demographics, including age and sex, and for atopic dermatitis. The outcome was incident asthma after the index event.
Key Findings
After matching and exclusions, the analysis included 344 children treated with dupilumab and 401 treated with budesonide. Asthma developed in 10.5% of the dupilumab group and 16.2% of the budesonide group, a risk difference of 5.7 percentage points (P=0.022). The risk ratio for asthma with budesonide versus dupilumab was 1.55 (95% CI, 1.06 to 2.27).
Asthma diagnoses during follow-up were also more frequent with budesonide, at a mean of 0.743 events per patient versus 0.369 with dupilumab (P=0.028).
“These results suggest that calming messages that trigger allergy reactions early in life might do more than help a child swallow,” Steinberger said in the news release. “It may also lower the chance that asthma will be the next allergic condition to develop.”
Limitations and Future Work
The study was observational and retrospective, so it shows an association only. The findings do not prove that dupilumab prevents asthma. Studies that follow children over time are needed to assess the effects of dupilumab on asthma risk.
Steinberger concluded that the results suggest early interruption of type 2 inflammation may alter progression of the atopic march in susceptible children, and that prospective studies are needed to determine whether dupilumab modifies the risk of asthma.



